Stephens Inc. AR Sells 3,948 Shares of Evolent Health, Inc. (NYSE:EVH)

Stephens Inc. AR decreased its position in Evolent Health, Inc. (NYSE:EVH) by 33.6% during the third quarter, HoldingsChannel reports. The firm owned 7,809 shares of the technology company’s stock after selling 3,948 shares during the quarter. Stephens Inc. AR’s holdings in Evolent Health were worth $221,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. US Bancorp DE raised its position in shares of Evolent Health by 180.3% in the third quarter. US Bancorp DE now owns 6,579 shares of the technology company’s stock valued at $186,000 after purchasing an additional 4,232 shares during the period. Values First Advisors Inc. grew its stake in shares of Evolent Health by 21.0% in the third quarter. Values First Advisors Inc. now owns 32,129 shares of the technology company’s stock worth $909,000 after acquiring an additional 5,583 shares during the last quarter. Moody Aldrich Partners LLC acquired a new stake in shares of Evolent Health in the third quarter worth $1,421,000. Friedenthal Financial acquired a new stake in shares of Evolent Health in the third quarter worth $723,000. Finally, Creative Planning grew its stake in shares of Evolent Health by 139.1% in the third quarter. Creative Planning now owns 43,262 shares of the technology company’s stock worth $1,223,000 after acquiring an additional 25,171 shares during the last quarter.

Evolent Health Stock Down 45.7 %

EVH opened at $13.35 on Friday. The company has a market capitalization of $1.55 billion, a P/E ratio of -14.67 and a beta of 1.58. The firm’s fifty day moving average price is $26.84 and its two-hundred day moving average price is $24.87. Evolent Health, Inc. has a fifty-two week low of $13.31 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.08 and a quick ratio of 1.08.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The company had revenue of $647.10 million during the quarter, compared to analysts’ expectations of $636.46 million. Evolent Health had a positive return on equity of 8.47% and a negative net margin of 3.16%. The business’s revenue was up 37.9% on a year-over-year basis. During the same period last year, the business earned $0.06 earnings per share. On average, analysts anticipate that Evolent Health, Inc. will post 0.84 EPS for the current year.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Evolent Health news, CEO Seth Blackley sold 187,904 shares of Evolent Health stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total transaction of $5,637,120.00. Following the completion of the transaction, the chief executive officer now directly owns 411,924 shares of the company’s stock, valued at approximately $12,357,720. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jonathan Weinberg sold 42,140 shares of Evolent Health stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total value of $1,314,768.00. Following the completion of the transaction, the general counsel now directly owns 167,027 shares of the company’s stock, valued at $5,211,242.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 307,291 shares of company stock valued at $9,290,385. 1.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EVH has been the topic of several research analyst reports. KeyCorp initiated coverage on shares of Evolent Health in a research note on Friday, October 11th. They issued an “overweight” rating and a $35.00 price objective on the stock. Oppenheimer lowered their price objective on shares of Evolent Health from $45.00 to $34.00 and set an “outperform” rating on the stock in a research note on Friday. JMP Securities lowered their price objective on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, August 9th. JPMorgan Chase & Co. raised their price objective on shares of Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Citigroup decreased their price target on shares of Evolent Health from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Evolent Health has an average rating of “Buy” and a consensus target price of $34.90.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.